INTRODUCTION

METHODS
This study is a substudy the Pediatric Randomized Early versus Deferred Initiation in Cambodia and Thailand study (The PREDICT study, clinicaltrials.gov identification number NCT00234091) (4).
Inclusion criteria
ART-naïve HIV infected children Aged 1-12 years Center for Disease Control and Prevention clinical classification N, A or B CD4 15%-24% No active infections
The children were randomized to either the immediate-arm in which started highly active antiretroviral therapy (HAART) at week 0 or the deferred-arm in which they were started HAART when a confirmed CD4% dropped to <15% or if the child developed symptoms of AIDS.
The children were followed and tested for CD4 every 12 weeks and HIV-RNA every 24 weeks until week 144. Virological failure (VF) was defined as HIV-RNA >1000 copies/ml. This substudy included data of children who had taken HAART ≥ 6 months.
Adherence monitoring tools
Adherence to ART was assessed by 3 adherence monitoring tools every 12 weeks including;
Tool 1: Announced pill count Nurses performed pill count and calculated percent adherence by pill count at each visit (took around 10 minutes/visit).
Percentage of adherence by pill count was calculated as [(dispensed drug -returned drug)/ estimated drug that patient should take in each period] x 100. Mean adherence by pill count before VF is defined as (sum of percent adherence by pill count recorded in each visit x duration on ART in that period)/total duration from starting ART until had VF. Poor adherence was defined as adherence by pill count <95%. Tool 2: Adherence Questionnaire by NIAID pediatric AIDS clinical trials group (PACTG) (5).
The primary caregiver was asked to complete the questionnaire (took around 10 minutes/visit). Any missed dose in the past 3 days before the visit was defined as poor adherence. Tool 3: 3-day self report
The investigator asked children or caregivers for any missed dose in the past 3 days (took around 1 minute/visit). Poor adherence was defined as any missed dose in the past 3 days before the visit.
Statistics
Adherence data were censored after VF. Longitudinal time to event analysis was used to evaluate predictors of poor adherence and VF. Odds ratio of poor adherence causing virologic failure was calculated by logistic regression. Kappa statistics were used to describe the agreement between each tool. 207 children were eligible for this substudy. All were perinatally HIV-infected children. Median (IQR) age was 7 (4-9) years. 92% received zidovudine/lamivudine/nevirapine as their first-line therapy. Other characteristics at ART initiation are presented in Table 1 .
Agreement between adherence monitoring tools
Between adherence monitoring tools Kappa agreement Tool-1 to Tool-2 0.14 (slight agreement) Tool-1 to Tool-3 0.10 (slight agreement) Tool-2 to Tool-3 0.37 (Fair agreement)
RESULTS
The PREDICT study is sponsored by National Institute of Allergy and Infectious Disease (NIAID), Grant number U19 AI053741, Clinical trial.gov identification number NCT00234091. Antiretoviral drugs for PREDICT are provided by GlaxoSmithKline (AZT, 3TC), BoehringerIngelheim (NVP), Merck (EFV), Abbott (RTV) and Roche (NFV). The study is partially funded by the National Research Council of Thailand. We are grateful to the children and their families for participating PREDICT. 
CONCLUSION
Treatment outcomes
During 144 weeks, 28 children (14%) had VF. Number of children with poor adherence by each tools and VF were shown in Table 2 .
Predictors of virologic failure
By multivariate analysis, predictor of VF was poor adherence by 3-day self report (5.0; 1.82-13.58) ( Table 3 ).
In our study, self-report of any missing dose during 3-day before each visit was independently associated with VF. There is no consensus among researchers for defining and measuring ART adherence in HIV-infected children. From a systematic review, Pediatric HIV care programs in low-and middle-income countries used heterogeneous methods to measure ART adherence (6). Pill counts revealed lower adherence estimates (6). Martin et al. reported reliability of Medication Event Monitoring System caps (MEMS cap) and also reported that pill counts offered comparable adherence data to MEMS cap and are less costly (7). New method to measure adherence is ART concentration in hair which is on-going in pediatric HIV trial (8). Note: Data of children were censored after having virologic failure; * Mean adherence by pill count < 95% before VF is defined as (sum of percent adherence by pill count recorded in each visit x duration on ART in that period)/total duration from starting ART until had VL failure 
DISCUSSION
